Leukemias and Myelodysplastic Syndromes

Expert faculty review and share their insights on key findings in leukemias and myelodysplastic syndromes presented at the 2023 ASH Annual Meeting. 

Share

Program Content

Activities

  • ASH 2023 Data in Leukemias and MDS
    Conference to Clinic: Leukemias and Myelodysplastic Syndromes
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 10, 2024

  • ASH 2023: Leukemias and MDS
    Key Studies in Leukemias and Myelodysplastic Syndromes: Independent Conference Coverage of ASH 2023
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 06, 2024

    Expires: March 05, 2025

Activities

COMMANDS Full Analysis
COMMANDS: Full Analysis of Phase III Trial of Luspatercept vs Epoetin alfa for ESA-Naive, Transfusion-Dependent, Lower-Risk MDS
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2023

IMerge Subgroup Analysis
Phase III IMerge Subgroup Analysis: Imetelstat for Achieving Transfusion Independence in ESA R/R or Ineligible Lower-Risk MDS
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2023

Retrospective STOP-VEN Study
STOP-VEN: Discontinuation of Venetoclax + Azacitidine for Patients With AML in Remission at Time of Treatment Interruption
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2023

Quizartinib, Ven, Dec in FLT3 ITD Mutated AML
Phase I/II Trial of Quizartinib, Venetoclax, and Decitabine in FLT3-ITD–Mutated AML
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2023

Oral AAA in ND APL
All-Oral Arsenic Trioxide–Based Induction in Newly Diagnosed Acute Promyelocytic Leukemia
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2023

ASCEND-CML
ASCEND-CML: Phase II Trial of Frontline Asciminib in Patients With CP-CML
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

Revumenib for Acute Leukemia
AUGMENT-101: Phase II Study of Revumenib for R/R KMT2Ar Acute Leukemia
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2023

QuANTUM-First  MRD Analysis
Phase III QuANTUM-First: Prognostic Value of FLT3-ITD–Specific MRD Clearance at Induction/Consolidation Using Chemotherapy With or Without Quizartinib in Patients With AML
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2023

STIMULUS-AML2
STIMULUS-AML2: Preliminary Safety of Sabatolimab Monotherapy in Patients With MRD+ AML After AlloSCT
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2023

Faculty

cover img faculity

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.